On Thursday, Shares of Bristol-Myers Squibb Co (NYSE:BMY), added 0.46% and closed at $50.24 in the last trading session. The last trading range of the stock ranges between $49.12 and $50.49. Bristol-Myers Squibb Company (BMY) declared recently updated results from two pivotal Phase 3 studies, CheckMate -057 and CheckMate -017, which showed more than one-third of formerly treated metastatic non-small cell lung cancer (NSCLC) patients in both trials practiced ongoing responses with Opdivo, contrast to no ongoing responses in the docetaxel arm. The median duration of response (DOR) with Opdivo as compared to docetaxel in CheckMate -057 was 17.2 months (95% CI: 8.4, NE) and 5.6 months (95% CI: 4.4, 6.9), respectively, and in CheckMate -017 it was 25.2 months (95% CI: 9.8, 30.4) and 8.4 months (95% CI: 8.4, NE), respectively. In CheckMate -057, patients with PD-L1 ≥1% had a median DOR of 17.2 months (95% CI: 8.4, NE) and in patients with PD-L1 <1%, it was 18.3 months (95% CI: 5.5, NE). In both studies, durability of response was observed in both PD-L1 expressors and non-expressors, and in CheckMate -057, one out of the four complete responses occurred in a patient with <1% PD-L1 expression.
There were no new safety signals identified for Opdivo in the pooled safety analysis from both studies. No new treatment-related deaths occurred between one and two years’ minimum follow-up despite the longer treatment exposure, and new events were observed in 11/418 patients with an additional one year of follow up.
These findings were presented recently, October 9, during a poster negotiation session at the 2016 European Society for Medical Oncology Congress from 3:46-4:06 p.m. CEST (Abstract #1215PD).
Endo International plc – Ordinary Shares (NASDAQ:ENDP), jumped 0.92% and closed at $19.81 in the last trading session. The last trading range of the stock ranges between $19.13 and $20.15. The company’s Market capitalization is $4.37 Billion with the total outstanding Shares of 222.77 million. Endo Pharmaceuticals Inc., a partner of Endo International plc (ENDP) (ENL.TO), recently declared new data to be presented evaluating the safety and efficacy of XIAFLEX®(collagenase clostridium histolyticum) (or CCH) injection under investigation for the treatment of palmar Dupuytren’s disease nodules. The findings will be presented during a podium presentation on Saturday, October 1, 2016 at 10:40 a.m. CDT at the annual meeting of the American Society for Surgery of the Hand (ASSH) held from September 29 to October 1, 2016 in Austin, Texas.
In a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study, in 75 adult study participants with Dupuytren’s disease and at least 1 nodule who received a single injection of CCH 0.40 mg or 0.60 mg, a statistically noteworthydecrease was shown from baseline in the mean nodule surface area (P≤0.001), consistency score (P<0.001) and hardness score (P≤0.01) at week 8 as compared to study participants receiving placebo. The safety profile of those treated with CCH was generally well tolerated. Adverse events included extremity pain, axillary pain, injection site-related adverse events and pruritus. One adverse event was stated as severe (injection site pain with CCH 0.60 mg). No patients were suspended from the study because of an adverse event.
Swift Transportation Co (NYSE:SWFT), dropped -3.64% and closed at $20.11 in the last trading session. The last trading range of the stock ranges between $19.97 and $20.44. During the 52-week trading session the minimum price at which share price traded, registered at $11.74 and reached to max level of $22.15. Swift Transportation Company (SWFT) will release its earnings for the third quarter ended September 30, 2016 after market close on Monday, October 24, 2016 in the form of a letter to stockholders. The letter will be published on the company’s website.
A conference call is planned for Tuesday, October 25, 2016 at 12:00 p.m. EDT, where Swift Transportation’s administration team will answer questions formerly presented.